Who’s Going to ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
450 organizations and 1,096 speakers, chairs and poster presenters at the European Society of Gene & Cell Therapy (ESGCT) 2026 Congress, a ~2,500-person, mostly academic meeting of gene and cell therapy researchers and clinicians. As of Oct 16, 2026.
Format
Topic
Top represented
Showing 1–1 of 450 organizations
| Organization | ESGCT 2026 Attendance |
|---|---|
Hannover Medical School Hannover, Germany | |
Medical university and hospital with research on AAV and lentiviral vectors, stem cell gene therapy and virus-specific T-cell therapy. | Chair Tue Oct 27 9:00am–10:45am EDUCATION SESSION 1a - Expanding the delivery possibilities by the design of new vectors for gene therapy Vectors and delivery (AAV, lentiviral, LNP) Workshop Tue Oct 27 9:30am–10:45am Adeno-associated virus (AAV) vectors – Insights into strategies for overcoming limitations in host-vector interactions Vectors and delivery (AAV, lentiviral, LNP) Chair Tue Oct 27 11:15am–1:00pm EDUCATION SESSION 2a - What human trials are teaching us Clinical trials and translation Workshop Tue Oct 27 11:40am–1:00pm Workshop Tue Oct 27 12:05pm–1:00pm Safety evaluations of CGT products in vitro and in vivo Clinical trials and translation Talk Tue Oct 27 6:30pm–7:30pm Cell-based therapy for amyloid pathology in Alzheimer's disease using engineered iPSC-Macs Cell therapies and CAR-T Talk Wed Oct 28 10:00am–10:30am In vivo targeting of hematopoietic stem cells by capsid-engineered AAV vectors Vectors and delivery (AAV, lentiviral, LNP) Talk Wed Oct 28 11:00am–12:30pm Tailored T-cell therapy for viral infections in immunocompromised patients Cell therapies and CAR-T Poster Wed Oct 28 1:30pm–3:30pm AAV-mediated delivery of SOD1 and Catalase protects against progressive and noise-induced hearing loss via a minimally invasive approach Poster Wed Oct 28 1:30pm–3:30pm Approaches to enhancing antigen-specific immune responses for advancing the prime-boost vaccination platform Poster Wed Oct 28 1:30pm–3:30pm Cryopreserved hematopoietic organoids for distributed and bioreactor-agnostic immune cell manufacturing Poster Wed Oct 28 1:30pm–3:30pm Development and validation of novel strategies to protect against drug-induced nephrotoxicity Poster Wed Oct 28 1:30pm–3:30pm Development of an iPSC-based high-throughput drug screening in Hereditary Pulmonary Arterial Hypertension Poster Wed Oct 28 1:30pm–3:30pm Engineering human iPSC-derived macrophages to decode antiviral stress and deploy regenerative signals Poster Wed Oct 28 1:30pm–3:30pm Generation of low Immunogenic livers by lentiviral vector-mediated genetic engineering delivered during ex-vivo liver perfusion Poster Wed Oct 28 1:30pm–3:30pm Generation of low immunogenic kidneys by downregulating mhc expression during ex vivo machine perfusion Poster Wed Oct 28 1:30pm–3:30pm HLA-Independent CLR-T Cells Targeting UL18 for Universal HCMV Immunotherapy Poster Wed Oct 28 1:30pm–3:30pm Human iPSC-derived macrophages retain functional stability after bronchoscopic lung delivery and enable non-invasive tracking Poster Wed Oct 28 1:30pm–3:30pm LNP-mediated DNA delivery achieves sustained Factor VIII expression in hemophilia A mice Poster Wed Oct 28 1:30pm–3:30pm LNP-mediated base editing reduces hepatic iron overload and modifies fibrosis- and HCC-associated gene expression in HFE-related hemochromatosis mice Poster Wed Oct 28 1:30pm–3:30pm Lipid nanoparticle-based approach for efficient prime editing and intravascular genetic repair of PAH disease-specific mutations Poster Wed Oct 28 1:30pm–3:30pm Scalable manufacturing of cryopreserved human iPSC-derived immunomodulatory macrophages for cell-based therapy of liver fibrosis Poster Wed Oct 28 1:30pm–3:30pm Self-assembling palmitoylated siRNA mediates efficient pulmonary RNAi treatment via inhalation Poster Wed Oct 28 1:30pm–3:30pm Single cell RNAseq-guided identification of a BKV protein VP1- and HLA-C*07:02-restricted TCR for personalized gene-engineered T cell therapy Poster Wed Oct 28 1:30pm–3:30pm Single-cell sequencing reveals antigen-specific T-cell expansion in a patient following adoptive T-cell therapy for progressive multifocal leukoencephalopathy Cell therapies and CAR-T Poster Wed Oct 28 1:30pm–3:30pm Systematic evaluation of tetraspanins for cargo engineering of MSC-derived extracellular vesicles Poster Wed Oct 28 1:30pm–3:30pm TCR-engineered T cells for HCMV treatment in immunocompromised patients Poster Wed Oct 28 1:30pm–3:30pm Vector-associated acute myeloid leukemia 16 years after gene therapy Talk Wed Oct 28 4:00pm–5:30pm Fit to serve - adapting biological nanoparticles by capsid engineering Vectors and delivery (AAV, lentiviral, LNP) Talk Thu Oct 29 9:30am–10:30am Clinical Proof-of-Concept for In Vivo Base Editing in PI*ZZ Alpha-1 Antitrypsin Deficiency: Results from the YOLT-202 Phase I/II Trial Gene and epigenome editingClinical trials and translation Poster Thu Oct 29 2:00pm–4:00pm A Novel Generation of AAV Vectors to Combat Liver Fibrosis and Improve Liver Transplantation Poster Thu Oct 29 2:00pm–4:00pm AAV-mediated auditory neuron protection (BRIDGE-BDNF): a promising approach for improved cochlear implant performance Poster Thu Oct 29 2:00pm–4:00pm Comparing ex vivo and in vivo performance of receptor binding mutants of adeno-associated virus vectors Poster Thu Oct 29 2:00pm–4:00pm Continuous generation of functional human iPSC-derived NK cells in a scalable hematopoietic organoid system Poster Thu Oct 29 2:00pm–4:00pm Designer lentiviral vectors for precision cell engineering Poster Thu Oct 29 2:00pm–4:00pm Dual T cell-tropic adeno-associated virus vectors platform for generating sustained CAR-T cells in vivo Poster Thu Oct 29 2:00pm–4:00pm Engineering sustainable CAR expression in iPSC and iPSC-derived NK cells through optimized vector and promoter design Poster Thu Oct 29 2:00pm–4:00pm FLT3L and SR1 Regulate Development and Immunostimulatory Function of Human PSC-Derived Dendritic Cells Poster Thu Oct 29 2:00pm–4:00pm Generation of designer regulatory T cells for improved transplantation Poster Thu Oct 29 2:00pm–4:00pm Genetically engineered T cells for targeted depletion of alloreactive B and T cells in solid organ transplantation – CORAT-Ts Poster Thu Oct 29 2:00pm–4:00pm Modeling clonal evolution in human HSPCs to predict insertional mutagenesis following gene therapy Poster Thu Oct 29 2:00pm–4:00pm Novel AAV9-based capsid variants combining immune-modulating features and muscle-tropism Poster Thu Oct 29 2:00pm–4:00pm Pan-cancer CD176-targeting armored CAR-Ts mediate specific elimination of malignant cells from different hematological and solid cancer entities Poster Thu Oct 29 2:00pm–4:00pm Single-cell RNA-seq unveils new immortalization markers of retroviral vector transformed mHSPCs Poster Thu Oct 29 2:00pm–4:00pm Single-cell profiling-guided development of CAR and TRUCK-like NK cell therapies for gynecological malignancies Poster Thu Oct 29 2:00pm–4:00pm Synthetic iPSC-derived macrophages programmed to convert tumor antigen recognition into phagocytosis and cytokine-driven reprogramming Poster Thu Oct 29 2:00pm–4:00pm Targeting Fibroblast Activation Protein through CAR immunotherapy for molecular image-guided cardiac repair Talk Thu Oct 29 4:00pm–6:00pm Machine learning–guided engineering of AAV2 vectors for selective outer hair cell targeting in the inner ear Vectors and delivery (AAV, lentiviral, LNP) Chair Thu Oct 29 6:30pm–7:30pm SESSION 10: Enabling technologies Manufacturing, CMC and access |
Instantly find 20 buyers from organizations at ESGCT 2026
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
When and where is ESGCT 2026?
ESGCT 33rd Annual Congress runs October 27–30, 2026, at the Congress Center Hamburg in Hamburg, Germany.
Where is the ESGCT 2026 program?
This guide lists every organization on the ESGCT 2026 program with its sessions; the full program is on the official website.
How do I register for ESGCT 2026?
Fees and registration are on the organizer's registration page.
What conference is this?
ESGCT 2026 is the European Society of Gene & Cell Therapy’s 33rd Annual Congress, held October 27–30, 2026 at the Congress Center Hamburg. It brings together gene and cell therapy researchers, clinicians and developers from universities, hospitals and biotech with the vector, CDMO and tools companies that serve them, across sessions on vectors and delivery, genome editing, cell therapies, clinical translation, manufacturing and rare disease.
What is in this guide?
Every organization we can place at ESGCT 2026: 1,096 speakers, chairs and poster presenters from the public programme and poster list (1,213 invited talks, oral abstracts, education and workshop talks, chaired sessions, company lunchtime symposia and posters) rolled up to their institutions and companies, and the 29 sponsors and supporters with their level — 450 organizations in one list. Nobody is named; a speaker counts toward their institution. ESGCT publishes no attendee list and no booth numbers.
How are organizations typed?
Universities and research institutes, hospitals and clinical centres, drug developers (large pharma and biotech), suppliers (vector and cell CDMOs, tools and reagent companies, other services) and agencies, societies and charities. The topic filters are judged from each talk’s and session’s title, and for a poster from the category its authors filed it under (posters filed under “Other” or “Disease Models” are judged from their title).
How current is it?
The programme, speaker list and sponsor list were pulled on October 8, 2026, and the organizer’s poster list on October 16, 2026, eleven days before the congress. A poster lists its presenting author only, so a co-author’s institution is not counted. Odd-numbered posters are presented in Poster Session I (Wednesday, October 28, 13:30–15:30) and even-numbered ones in Poster Session II (Thursday, October 29, 14:00–16:00). A few invited talks were still untitled; they appear under their session’s title.
Browse ESGCT 2026 by
Topic
Everyone
Organizations with their own page
250 organizations — every exhibitor and every organization with 2 or more presentations.
- 4basebio
- Aarhus University
- AAVnerGene
- Addition Therapeutics
- Aga Khan University
- AGC Biologics
- Agilent
- Aix-Marseille University
- Akribion Therapeutics
- Alaya.bio
- Amsterdam UMC
- Andelyn Biosciences
- Annogen
- Apertura Gene Therapy
- Aristotle University of Thessaloniki
- ART-TG (Inserm US35)
- Asahi Kasei Life Science
- Ascend Advanced Therapies
- ASGCT
- AstraZeneca
- Atsena Therapeutics
- Autonomous University of Barcelona
- AviadoBio
- Bambino Gesù Children's Hospital
- Banc de Sang i Teixits
- Bar-Ilan University
- Basecamp Research
- Baylor College of Medicine
- Beckman Coulter Life Sciences
- Benitec Biopharma
- Berlin Institute of Health at Charité (BIH)
- Bielefeld University
- Biomay
- BioNTech
- Boehringer Ingelheim
- Boston Children's Hospital
- Broad Institute
- c-LEcta
- Cabaletta Bio
- Cancer Research Center of Toulouse (CRCT)
- Cardiff University
- Castalysis Bioscience
- CEA
- CEINGE Biotecnologie Avanzate
- Cell and Gene Therapy Catapult
- Cellectis
- cellvie
- Centre for Stem Cell Research (CSCR)
- Cerba Research
- Certest Biotec
- Charité – Universitätsmedizin Berlin
- Children's Medical Research Institute
- CIEMAT
- CIMA University of Navarra
- Circio
- Coave Therapeutics
- Complement Therapeutics
- Concinnity Genetics
- Corning
- CPTx
- Curapath
- Cyagen
- Cytiva
- DINAMIQS
- Dyno Therapeutics
- Editas Medicine
- Erasmus MC
- EuroGCT
- European Health and Digital Executive Agency (HaDEA)
- European Research Council
- Evotec
- Ewha Womans University
- Eye & ENT Hospital of Fudan University
- Francis Crick Institute
- Fraunhofer Institute for Cell Therapy and Immunology (IZI)
- Fred Hutchinson Cancer Center
- FUJIFILM Wako Chemicals Europe
- GeneMedi
- GeneT Gene Therapy Center of Excellence
- Genethon
- Genezen
- GENYO
- German Cancer Research Center (DKFZ)
- German Red Cross Blood Service Baden-Württemberg–Hessen
- German Sport University Cologne
- GET-IN
- Goethe University Frankfurt
- Green Elephant Biotech
- Hannover Medical School
- Hanyang University
- Harvard University
- Heidelberg University
- Heidelberg University Hospital
- Helmholtz Munich
- Hirszfeld Institute of Immunology and Experimental Therapy
- Human Gene Therapy
- iBET
- IDIBAPS
- Ikarovec
- Imagine Institute
- INITS
- Inside Therapeutics
- Institut Curie
- Institut Pasteur
- Institute of Biomedicine of Seville (IBiS)
- Institute of Molecular and Clinical Ophthalmology Basel (IOB)
- Integra Therapeutics
- International Centre for Genetic Engineering and Biotechnology (ICGEB)
- Isolere Bio
- IWT Pharma
- Jagiellonian University
- Jesús Usón Minimally Invasive Surgery Centre (CCMIJU)
- Jichi Medical University
- Johnson & Johnson Innovative Medicine
- KACTUS
- King's College London
- Kodo LifeScience
- Koç University
- KTH Royal Institute of Technology
- KU Leuven
- Kyoto Prefectural University of Medicine
- Kyung Hee University
- Latus Bio
- Laverock Therapeutics
- Leiden University Medical Center
- Leipzig University
- Lir Therapeutics
- LMU Munich
- Lonza
- Max Delbrück Center
- McGill University
- MedChemExpress
- Medical Center – University of Freiburg
- MeiraGTx
- Merck KGaA
- Miltenyi Biotec
- Minaris Advanced Therapies
- Mirus Bio
- Mission Bio
- NanoFCM
- Nantes Université
- National Institute of Biology (NIB)
- National Institute of Health Doutor Ricardo Jorge (INSA)
- National Institutes of Health
- NecstGen
- Neurogene
- Neurum Diabetic Care Center
- New England Biolabs
- NHS Blood and Transplant
- Nionyx Bio
- Novartis
- Novogene
- Orchard Therapeutics
- OXB
- PackGene
- Paris Brain Institute
- PathoQuest
- Paul-Ehrlich-Institut
- PhoenixBio
- PlasmidFactory
- Powered Research
- PROGEN
- Promega
- ProtaGene
- QIAGEN
- Ramon Llull University
- Reforgene Medicine
- ReiThera
- Revvity
- Roche
- Roche CustomBiotech
- Roche Diagnostics
- San Raffaele Hospital
- Sanofi
- Sartorius
- SCIEX
- Sensorion
- Solid Biosciences
- SR-Tiget
- Stanford University
- Svar Life Science
- Synthego
- Technical University of Munich
- The Cyprus Institute of Neurology and Genetics
- The Jikei University School of Medicine
- Thermo Fisher Scientific
- Tigem
- Touchlight
- TRON
- TU Dresden
- TUM University Hospital
- uBriGene Biosciences
- UMass Chan Medical School
- uniQure
- Univercells Technologies
- University College Dublin
- University College London
- University Hospital Erlangen
- University Hospital Essen
- University Hospital Tübingen
- University Hospital Würzburg
- University Hospital Zurich
- University Medical Center Göttingen
- University Medical Center Hamburg-Eppendorf
- University Medical Center Utrecht
- University of A Coruña
- University of Aveiro
- University of Bristol
- University of Copenhagen
- University of Eastern Finland
- University of Eastern Piedmont
- University of Edinburgh
- University of Florida
- University of Freiburg
- University of Geneva
- University of Granada
- University of Groningen
- University of Guelph
- University of Hamburg
- University of Helsinki
- University of Lausanne
- University of Lisbon
- University of Modena and Reggio Emilia
- University of Naples Federico II
- University of Oxford
- University of Padua
- University of Pavia
- University of Santiago de Compostela
- University of Siena
- University of the Witwatersrand
- University of Trento
- University of Tübingen
- University of Veterinary Medicine Hannover
- University of Vienna
- University of Zurich
- Université Marie et Louis Pasteur
- Université Paris-Saclay
- Utrecht University
- Vall d'Hebron Institute of Oncology (VHIO)
- VectorBuilder
- VectorY Therapeutics
- Veneto Institute of Oncology (IOV-IRCCS)
- Viralgen
- VIVEbiotech
- Vivet Therapeutics
- Wacker
- Waker Bioscience
- Westmead Institute for Medical Research
- WhiteLab Genomics
- Witten/Herdecke University
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction